T1	p 173 236	patients with chronic heart failure after myocardial infarction
T2	p 373 407	patients with heart failure ( HF )
T3	p 575 635	patients with class II to IV HF and ejection fraction < 35 %
T4	p 793 914	Of 330 patients intended for enrollment , 23 were randomized ( MARVEL-1 ) before stopping the study for financial reasons
T5	p 1481 1535	HF patients with chronic postinfarction cardiomyopathy
T6	p 1849 1895	HF patients with postinfarction cardiomyopathy
T7	i 118 148	skeletal myoblast implantation
T8	i 360 369	myoblasts
T9	i 528 535	placebo
T10	i 539 548	myoblasts
T11	i 994 1001	placebo
T12	i 1132 1148	myoblast-treated
T13	i 1164 1171	placebo
T14	i 1278 1294	myoblast-treated
T15	i 1570 1579	myoblasts
T16	i 1718 1726	myoblast
T17	i 1822 1830	myoblast
T18	o 81 87	safety
T19	o 92 114	cardiovascular effects
T20	o 277 283	safety
T21	o 300 308	efficacy
T22	o 662 708	frequency of serious adverse events ( safety )
T23	o 713 742	changes in 6-minute walk test
T24	o 747 790	Minnesota Living With HF score ( efficacy )
T25	o 1062 1096	Ventricular tachycardia responsive
T26	o 1245 1264	functional capacity
T27	o 1432 1463	Minnesota Living With HF scores